---
schema_version: "secwatch.filing_event.v1"
accession: "0001357459-26-000025"
form_type: "8-K"
ticker: "PALI"
cik: "0001357459"
company_name: "PALISADE BIO, INC."
filed_at: "2026-11-10T21:22:49+00:00"
generated_at: "2026-11-10T21:24:12.150314+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Palisade Bio Q3 net loss widens to $14.6M; ASCENTRA-UC dosing underway, topline set for Q4 2027

## Summary
- Net loss $14.6M ($0.07/share) vs $2.9M ($0.38/share) in Q3 2025; R&D rose to $10.6M from $1.4M and G&A to $5.1M from $1.5M on PALI-2108 Phase 2 costs.
- Cash and equivalents of $113.6M at September 30, 2026; company says this funds operations through the ASCENTRA-UC (Q4 2027) and ASCENTRA-CD (Q1 2028) efficacy readouts.
- First patient dosed in Phase 2b ASCENTRA-UC on October 27, 2026; 29 of 30 U.S. sites activated, ~115 sites planned globally, ~204 patients, 15 mg and 30 mg vs placebo.
- FDA cleared the Crohn's disease IND on September 22, 2026; Phase 2a ASCENTRA-CD (~60 patients, 30 mg once daily) enrollment targeted Q1 2027, primary readout Q1 2028.
- Presented five posters at ACG 2026 and one oral plus three moderated posters at UEG Week 2026, including endoscopic improvement within two weeks in five fibrostenotic Crohn's patients.

## SEC filing metadata
- accession: 0001357459-26-000025
- form_type: 8-K
- ticker: PALI
- cik: 0001357459
- company_name: PALISADE BIO, INC.
- filed_at: 2026-11-10T21:22:49+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357459/000135745926000025/0001357459-26-000025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357459/000135745926000025/pali-20261110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001357459-26-000025
- JSON: https://secwatch.observer/filing/0001357459-26-000025.json
- Plain text: https://secwatch.observer/filing/0001357459-26-000025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.